Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study

BACKGROUND: Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast/gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer (mCRC). MyPathway evaluates the efficacy of targeted therapies in non-indicated tumour types with pote...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Meric-Bernstam, Funda, Hurwitz, Herbert, Kanwal Pratap Singh, Raghav, McWilliams, Robert R., Fakih, Marwan, VanderWalde, Ari, Swanton, Charles, Kurzrock, Razelle, Burris, Howard, Sweeney, Christopher, Bose, Ron, Spigel, David R., Beattie, Mary S., Blotner, Steven, Stone, Alyssa, Schulze, Katja, Cuchelkar, Vaikunth, Hainsworth, John
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781620/
https://ncbi.nlm.nih.gov/pubmed/30857956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30904-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi